Sector News

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

July 22, 2019
Life sciences

The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more.

This IPO is one of the biggest in biotech history, behind the whopping €530M Nasdaq entry from US mRNA biotech Moderna last year. It’s also to be expected, coming from the company that developed the blockbuster blood cancer drug Darzalex in partnership with Janssen.

Genmab will use the money to push the development of its antibody drugs. The company has two antibodies in phase III, one being developed with Novartis for the treatment of the neurological disease multiple sclerosis, and the other with Horizon Pharma for the treatment of thyroid-related eye disease. Genmab has many other partnered and proprietary programs ongoing, including developing a preclinical drug with Janssen with the potential to outperform Darzalex in some tumor types.

With a market cap of over €10B ($11B), Genmab’s position as Europe’s most valuable biotech is secure for the time being. The company has proved popular with investors since the beginning, with a record IPO of €210M on the Copenhagen Stock Exchange back in 2000, just a year after it was founded.

By: Jonathan Smith

Source: Labiotech.eu

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).